In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
List view / Grid view
Groundbreaking study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.
Researchers have revealed a new substance that can bind well to serotonin transporters, offering a potential way to lessen the side effects of antidepressant therapies.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
The mechanism in the brain connecting chronic pain and depression could lead to treatments for both, according to researchers.
A study has discovered a molecule key in neuronal growth that could be used as a drug target to treat anxiety-related diseases.
Researchers have identified a tiny hidden pocket on the NMDA receptor that could be targeted to treat strokes and seizures...